BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Advancing MS1819 in Fight to Improve Treatment of EPI in CF, CP Patients

December 11, 2020 14:36:26

AzurRx BioPharma (NASDAQ: AZRX) is focused on the development of its lead drug candidate, MS1819, for exocrine pancreatic insufficiency (“EPI”) in patients suffering from cystic fibrosis (“CF”) and chronic pancreatitis (“CP”). While CF is a relatively rare genetic disease, innovative and effective therapies are needed. CF is a dangerous condition that affects multiple body functions and organs, putting patients at risk of developing severe life-threatening illnesses. Technological advances have greatly increased the life span for CF patients. While children with CF rarely made it to elementary school age in the 1950s, the median age of survival for a CF patient is now around 47 years, with many patients living into their 60s ( A recent article discusses AZRX’s positioning amid the work in targeted treatments. It reads, “Due to the efforts of companies such as AzurRx BioPharma, the life span and quality of life of CF patients could be further improved. AzurRx’s lead product is MS1819, a recombinant lipase that could potentially change the treatment of exocrine pancreatic insufficiency in CF and CP patients.”

To view the full article, visit

About AzurRx BioPharma Inc.

AzurRx BioPharma is a biopharmaceutical company specializing in the research and development of non-systemic biologics for gastrointestinal disorders. The company is focused on the development of its lead drug candidate, MS1819. AzurRx is currently conducting two Phase 2 clinical trials of MS1819: the OPTION 2 monotherapy trial and the combination therapy trial consisting of MS1819 in conjunction with porcine-derived pancreatic enzyme replacement therapy, the current standard of care. The company is headquartered in Delray Beach, Florida, with clinical operations in Hayward, California. For more information, visit the company’s website at

NOTE TO INVESTORS: The latest news and updates relating to AZRX are available in the company’s newsroom at

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:

BioMedWire (BMW)
San Francisco, California
415.949.5050 Office

BioMedWire is part of the InvestorBrandNetwork